PDE4D抗体;PDE4D Antibody—艾普蒂

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Hela cells, Primary antibody: P12035(PDE4D Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 3 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human brain tissue using P12035(PDE4D Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12035(PDE4D Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

**Background of PDE4D Antibodies**

Phosphodiesterase 4D (PDE4D) is a member of the PDE4 enzyme family, which hydrolyzes cyclic adenosine monophosphate (cAMP), a critical secondary messenger regulating cellular signaling pathways. PDE4D is particularly notable for its role in modulating inflammation, neuronal function, and immune responses. It is expressed in various tissues, including the brain, lungs, and immune cells, and exists as multiple isoforms due to alternative splicing, enabling functional diversity. Dysregulation of PDE4D has been implicated in neuropsychiatric disorders (e.g., schizophrenia, Alzheimer’s disease), chronic obstructive pulmonary disease (COPD), and asthma, making it a therapeutic target of interest.

PDE4D-specific antibodies are essential tools for studying its expression, localization, and activity in biological systems. They enable researchers to detect PDE4D protein levels via techniques like Western blotting, immunohistochemistry, or flow cytometry, aiding in the exploration of its role in disease mechanisms. Additionally, these antibodies are used to validate PDE4D as a target in drug discovery, particularly for developing PDE4 inhibitors with potential anti-inflammatory or neuroprotective effects.

Recent studies highlight PDE4D's interaction with signaling pathways like β-adrenergic and cAMP-dependent pathways, further emphasizing its therapeutic relevance. However, challenges remain in isoform-specific targeting due to structural similarities within the PDE4 family. Advances in antibody engineering, including monoclonal and phospho-specific antibodies, continue to enhance specificity and utility in both research and clinical contexts. Overall, PDE4D antibodies bridge basic research and translational applications, offering insights into disease biology and therapeutic development.